Month 10 Analysis (Presented at Angiogenesis 2023) Month 7 Analysis (Presented at AAO 2022) 1 OTX - TKI U.S. - based Wet AMD Clinical Trial Design OTX - TKI Arm Aflibercept Arm OTX - TKI 600 g single implant injection Af

Month 10 Analysis (Presented at Angiogenesis 2023) Month 7 Analysis (Presented at AAO 2022) 1 OTX - TKI U.S. - based Wet AMD Clinical Trial Design OTX - TKI Arm Aflibercept Arm OTX - TKI 600 g single implant injection Aflibercept 2mg injection Sham injection Study Visit Multicenter, Randomized, Double - masked Trial Screening Key Inclusion Criteria Sub foveal neovascularization secondary to AMD Controlled fluid Previously treated with anti - VEGF injections Rescue Anti - VEGF Injection Criteria: Loss of 10 letters from best previous BCVA with current BCVA worse than baseline, or Evidence of 75 m CSFT increase from previous best value and 5 letters loss from best previous BCVA, or New macular hemorrhage Baseline Month 12 Analysis 0 4 8 12 16 20 24 28 32 36 40 44 48 52 Study Visits (Weeks) AAO=American Academy of Ophthalmology; AMD=age - related macular degeneration; BCVA=best corrected visual acuity; BL=baseline; CSF T=central subfield thickness; AMD=age - related macular degeneration; VEGF=vascular endothelial growth factor OTX - TKI subjects are followed past Week 52 Randomization 3:1 (OTX - TKI : Aflibercept) R

2 Baseline Characteristics Baseline Characteristic OTX - TKI (N=16) Aflibercept (N=5) Mean (SD) Age, Years 76 (8) 84 (8) Male, n (%) Female, n (%) 8 (50) 8 (50) 3 (60) 2 (40) Mean (SD) Months since wet AMD diagnosis 18 (12) 18 (12) Mean (SD) Number of anti - VEGF Injections within 12 Months Prior to baseline* 8 (3) 8 (4) Mean (SD) BCVA in ETDRS Letters 70.9 (17.7) 73.8 (9.0) Mean (SD) CSFT, m 273.8 (43.0) 240.6 (29.6) *Annualized data Includes one subject not treated per protocol who has been removed from efficacy analysis as subject incorrectly received afl ibe rcept instead of sham injection at Month 3 and 5 visits Data cut off April 14, 2023 BCVA=best corrected visual acuity; CSFT =c entral subfield thickness; ETDRS = Early Treatment Diabetic Retinopathy Study; AMD = age - related macular degeneration; SD = standard deviation; VEGF = vascular endothelial growth factor

-52 -48 -44 -40 -36 -32 -28 -24 -20 -16 -12 -8 -4 0 4 8 12 16 20 24 28 32 36 40 44 48 52 Weeks OTX - TKI (n=15) Aflibercept (n=5) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Reduction in Anti - VEGF Injections Following OTX - TKI at 12 Months 89% reduction in treatment burden with OTX - TKI at 12 months Ranibizumab Faricimab OTX - TKI 600 g implant Unspecified anti - VEGF agent Bevacizumab Rescue injection given at investigator's discretion (rescue criteria not met ) Post - Treatment Pre - Treatment 3 Data cut off April 14, 2023; per protocol analysis Reduction in treatment burden calculation includes all rescue injections Sham injection was given at Week 0 in the Aflibercept Arm and at Weeks 12, 20, 28, 36 and 44 in the OTX - TKI Arm (not shown). At Week 52, subjects in the aflibercept group were treated with wet AMD standard of care at the investigator's discretion. Rescue injection given (rescue criteria met ) Aflibercept

100% 100% 93% 93% 80% 73% 73% 73% 73% 67% 67% 60% 0% 20% 40% 60% 80% 100% Percentage of OTX - TKI Subjects Rescue - Free Up to Each Visit (n=15) 4 OTX - TKI Demonstrated Extended Duration of Action 60% were rescue - free up to 12 months with 4 additional subjects rescued at 12 months Data cut off April 14, 2023 Rescue - free rate calculations: If subjects received rescue anti - VEGF therapy at a study visit, those were reflected to count at the following study visit in the graph above Percentages presented in the graph above represent rescue - free rates up to each study visit, except for the 33% at Week 52 which includes rescue injections given at the Week 52 study visit 15/15 14/15 14/15 12/15 11/15 11/15 11/15 15/15 11/15 Rescue - free Subjects, n/N 10/15 9/15 10/15 Week 8 Week 12 Week 16 Week 20 Week 24 Week 28 Week 32 Week 36 Week 40 Week 44 Week 48 Week 52 33% inclusive of Week 52 Implant bioresorbs ~8 - 9 months

5 Vision and CSFT with OTX - TKI were Comparable to Aflibercept Q8W -70 -50 -30 -10 10 30 50 70 BL W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52 Mean CSFT Change from Baseline, m Mean Change in CSFT -15 -10 -5 0 5 10 15 BL W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52 Mean BCVA Change from Baseline, ETDRS Letters Mean Change in BCVA Aflibercept Q8W (n=5) OTX-TKI (censoring rescued subjects)* OTX-TKI (n=15) Mean baseline CSFT OTX - TKI: 269.2 (40.3) m Aflibercept Q8W: 240.6 (29.6) m Mean baseline BCVA OTX - TKI: 73.7 (14.4) letters Aflibercept Q8W: 73.8 (9.0) letters Mean (SD) change in BCVA from baseline to Week 52: D ata cut off April 14, 2023 Error bars represent standard deviation; n=14 in OTX - TKI arm at Weeks 8, 28, 40 and 48 due to missed visits *Sample size for OTX - TKI (censoring rescued subjects): n=15 at Baseline and Weeks 4 and 12; n=14 at Week 8 (missed visit) and We eks 16 and 20; n=12 at Week 24 and n=11 at Weeks 28, 32, 36 and 40; n=10 at Week 44; n=9 at Weeks 48 and 52 BCVA=best corrected visual acuity; BL=baseline; CSFT=central subfield thickness; ETDRS=Early Treatment Diabetic Retinopathy S tud y; W, week OTX - TKI: - 1.0 (6.0) letters Aflibercept Q8W: +2.0 (7.2) letters OTX - TKI: +0.6 (2.6) letters (censoring rescued subjects) Mean (SD) change in CSFT from baseline to Week 52: OTX - TKI: +20.2 (41.6) m Aflibercept Q8W: - 2.2 (8.5) m OTX - TKI: +17.2 (47.6) m (censoring rescued subjects)

6 Safety Summary OTX - TKI n=16 Aflibercept n=5 Subjects with Adverse Events in the Study Eye, n (%) Elevated IOP 2 (12.5) 1 (20.0)** Retinal detachment 0 0 Retinal vasculitis 0 0 Implant migration into the anterior chamber 0 NA Acute endophthalmitis 1 (6.25)* 0 Subjects with Ocular Adverse Events in the Study Eye Reported by Severity, n (%) Ocular AEs 16 (100.0) 3 (60.0) Mild 14 (87.5) 2 (40.0) Moderate 2 (12.5)* 1 (20.0)** Severe 0 0 Serious AEs 1 (12.5)* 0 No reports of drug - related ocular or systemic SAEs in either arm One event of acute endophthalmitis in OTX - TKI arm which occurred following mandated aflibercept injection at Month 1 Reported as moderate Injection procedure related Unrelated to the study drug Resolved after intravitreal antibiotic injection, with vision returning to baseline All events were mild except Acute endophthalmitis SAE (moderate and resolved) and worsening of cataract (moderate) in OTX - TKI arm Elevated IOP in aflibercept arm (moderate and resolved) *Moderate and serious ocular AE in OTX - TKI arm was Acute Endophthalmitis 6 days after mandated aflibercept injection at Month 1 **Moderate AE in Aflibercept arm was Elevated Intraocular pressure Data cut off April 14, 2023 IOP=intraocular pressure; SAE=serious adverse event